Literature DB >> 15102585

Selective serotonin re-uptake inhibitors in anorexia nervosa.

Meera Vaswani1, Harish Kalra.   

Abstract

Anorexia nervosa (AN), one of the major eating disorders, is a primarily psychiatric illness affecting a number of adolescents and young adults. AN usually runs a chronic course and is associated with significant morbidity and mortality. Drug therapy has modest success in its treatment. Various pharmacotherapeutic agents are being tested, with variable success. Selective serotonin re-uptake inhibitors are the one class of drug that has been found to be effective in AN, especially in preventing relapse. This article provides an overview of the current literature on the role of selective serotonin re-uptake inhibitors in the treatment of AN.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102585     DOI: 10.1517/13543784.13.4.349

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  3 in total

1.  4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter.

Authors:  Ernesto Solis; Igor Zdravkovic; Ian D Tomlinson; Sergei Y Noskov; Sandra J Rosenthal; Louis J De Felice
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

2.  Electrophysiological Actions of Synthetic Cathinones on Monoamine Transporters.

Authors:  Ernesto Solis
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 3.  Eating disorders in women.

Authors:  Pratap Sharan; A Shyam Sundar
Journal:  Indian J Psychiatry       Date:  2015-07       Impact factor: 1.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.